{"id":"NCT03296527","sponsor":"Ferring Pharmaceuticals","briefTitle":"Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Pan-Asian Women","officialTitle":"A Randomised, Controlled, Assessor-blind, Parallel Groups, Multicentre, Pan-Asian Trial Comparing the Efficacy and Safety of FE 999049 With Follitropin Alfa (GONAL-F) in Controlled Ovarian Stimulation in Women Undergoing Assisted Reproductive Technology Programme","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-12-01","primaryCompletion":"2020-01-03","completion":"2020-07-26","firstPosted":"2017-09-28","resultsPosted":"2021-06-01","lastUpdate":"2023-08-24"},"enrollment":1011,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Controlled Ovarian Simulation"],"interventions":[{"type":"DRUG","name":"Follitropin alfa","otherNames":["GONAL-F"]},{"type":"DRUG","name":"Follitropin delta","otherNames":["FE 999049","REKOVELLE"]}],"arms":[{"label":"Follitropin delta","type":"EXPERIMENTAL"},{"label":"Gonal-F","type":"ACTIVE_COMPARATOR"}],"summary":"To demonstrate non-inferiority of FE 999049 compared with GONAL-F with respect to ongoing pregnancy rate in women undergoing controlled ovarian stimulation.","primaryOutcome":{"measure":"Ongoing Pregnancy Rate","timeFrame":"10-11 weeks after transfer","effectByArm":[{"arm":"FE 000049 (Follitropin Delta)","deltaMin":31.3,"sd":null},{"arm":"GONAL-F (Follitropin Alfa)","deltaMin":25.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"20 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":13,"exclusionCount":28},"locations":{"siteCount":26,"countries":["China","South Korea","Taiwan","Vietnam"]},"refs":{"pmids":["34179971","36195924","37156263"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":30,"n":499},"commonTop":["Ovarian hyperstimulation syndrome","Pelvic discomfort","Biochemical pregnancy","Haemorrhage in pregnancy"]}}